CAMP

Analyst Sentiment

Wall St. Consensus
Buy
24 analysts·High coverage
67
Score
17 Buy (71%)6 Hold (25%)1 Sell (4%)
Rating Breakdown
Strong Buy
00%
Buy
1771%
Hold
625%
Sell
14%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$6.50
+46.1%
Consensus
$10.75
+141.6%
Bull
$15.00
+237.1%
12-Month Target Range24 analysts
$6.50$10.75$15.00
Current $4.45Consensus
Current Price
$4.45
Upside to Consensus
$6.30

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-28.54%
EPS
FY2028
Rev-61.69%
EPS
FY2029
Rev+341.02%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$7M$5M$2M$9M$19M
Low$3M$4M$1M$4M$10M
High$10M$6M$3M$12M$25M
EBITDA Avg$-5M$-3M$-1M$-5M$-12M
Low$-6M$-4M$-2M$-7M$-16M
High$-2M$-2M$-625,117$-3M$-6M
EBIT Avg$-5M$-3M$-1M$-6M$-12M
Low$-7M$-4M$-2M$-8M$-16M
High$-2M$-2M$-640,691$-3M$-6M
Net Income Avg$-31M$-23M$-23M$-20M$-20M
Low$-40M$-27M$-30M$-29M$-29M
High$-22M$-18M$-16M$-7M$-7M
EPS Avg$-1.10$-0.73$-0.73$-0.65$-0.67
Low$-1.31$-0.90$-0.98$-0.95$-0.97
High$-0.73$-0.59$-0.51$-0.23$-0.24
Analysts (Rev / EPS)6 / 55 / 54 / 52 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$2M$2M$2M$2M$2M$778,500$1M$1M
Low$1M$1M$1M$1M$683,969$348,361$579,035$579,035
High$3M$3M$4M$4M$2M$1M$2M$2M
EBITDA Avg$-1M$-1M$-1M$-1M$-945,824$-481,729$-800,717$-800,717
Low$-2M$-2M$-2M$-2M$-1M$-741,321$-1M$-1M
High$-649,006$-649,006$-668,979$-668,979$-423,234$-215,563$-358,302$-358,302
EBIT Avg$-1M$-1M$-2M$-2M$-969,388$-493,731$-820,666$-820,666
Low$-2M$-2M$-2M$-2M$-1M$-759,790$-1M$-1M
High$-665,175$-665,175$-685,646$-685,646$-433,779$-220,933$-367,229$-367,229
Net Income Avg$-10M$-9M$-9M$-9M$-10M$-11M$-13M$-13M
Low$-13M$-11M$-15M$-16M$-17M$-18M$-22M$-22M
High$-8M$-8M$-2M$-3M$-3M$-3M$-4M$-4M
EPS Avg$-0.17$-0.16$-0.15$-0.16$-0.17$-0.18$-0.23$-0.23
Low$-0.22$-0.19$-0.25$-0.27$-0.29$-0.31$-0.39$-0.38
High$-0.13$-0.13$-0.04$-0.05$-0.05$-0.05$-0.06$-0.06
Analysts (Rev / EPS)4 / 34 / 32 / 12 / 12 / 12 / 11 / 21 / 2

Earnings Surprises

Recent Analyst Actions

Aug 14, 2026UBS
Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler
Target:$15.00
+232.6%from $4.51
Jun 10, 2026Chardan Capital
Camp4 Therapeutics initiated with a Buy at Chardan
Target:$6.50
+62.1%from $4.01
Oct 2, 2025Cantor Fitzgerald
Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald
Target:$7.00
+137.3%from $2.95
Nov 5, 2024Leerink Partners
Leerink Partners Starts CAMP4 Therapeutics Corp (CAMP) at Outperform
Target:$17.00
+77.1%from $9.60
Nov 5, 2024Piper Sandler
Piper Sandler Starts CAMP4 Therapeutics Corp (CAMP) at Overweight
Target:$18.00
+87.5%from $9.60
Aug 16, 2022Craig-Hallum
Craig-Hallum upgrades CalAmp to Buy, raises price target to $10
Target:$10.00
+72.4%from $5.80
Jun 24, 2022Goldman Sachs
Goldman Sachs cuts CalAmp EBITDA estimates on lower margin forecasts
Target:$5.00
+1.4%from $4.93
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.